Nurix Therapeutics(NRIX)
BRISBANE, CA
BiotechnologyFocus: Small Molecules, Protein Degradation
Nurix Therapeutics is a life sciences company focused on Small Molecules, Protein Degradation.
Oncology
Funding Stage
PUBLIC
Open Jobs
3
Pipeline & Clinical Trials
NX-1607
Ovarian Cancer, EpithelialClinical Trials (1)
NCT05107674A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1Phase 1
Clinical Trials (1)
NCT05131022A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1NX-5948
Healthy VolunteerClinical Trials (1)
NCT06717269Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Phase 1Phase 1
Clinical Trials (1)
NCT04830137A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1Drug Product De-TIL-0255
Platinum-resistant Ovarian CancerClinical Trials (1)
NCT05107739A Study of DeTIL-0255 in Adults With Advanced Malignancies
Phase 1NX-5948
Healthy VolunteerClinical Trials (1)
NCT06691828Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948
Phase 1Phase 1
Clinical Trials (1)
NCT06593457A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
Phase 1Phase 2
Clinical Trials (1)
NCT07221500A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2Open Jobs (3)
Interview Prep Quick Facts
Portfolio: 8 clinical trials
SEC Filings: 2 available
Open Roles: 3 active jobs
Financials (FY2025)
Revenue
$77M99%
R&D Spend
$189M(246%)3%
Net Income
-$144MCash
$55MHiring Trend
Stable
3
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles